Industry Research Reports

Home > Reports > Service & Software > Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Service & Software

Published Date: 2026-03-12

Pages: 98 Pages

Report ld: 6225709

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Neurodegenerative Disease CDMO Market Size(US$)

CAGR 2026-2032

6.9%

Market Size,2032

USD 1,220

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 818 million

Market Forecast in 2032(Value)

US$ 1,220 million

CAGR

6.9%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Neurodegenerative Disease CDMO market size was US$ 770 million in 2025 and is forecast to reach a readjusted size of US$ 1220 million by 2032 with a CAGR of 6.9% during the forecast period 2026-2032.

Neurodegenerative disease CDMO is a contract research and development and manufacturing organization that focuses on the field of neurodegenerative diseases and provides pharmaceutical companies and scientific research institutions with a full range of services from drug discovery, preclinical research to commercial production. Its core is to develop innovative therapies for the complex pathologies of diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (such as abnormal protein aggregation, neuroinflammation, mitochondrial dysfunction, etc.) by integrating professional technology platforms such as neuroscience, protein engineering, cell therapy, and gene therapy. It also relies on a deep understanding of the special requirements of regulatory agencies such as the FDA and EMA (such as biomarker verification and long-term safety assessment) to ensure that research and development and production meet international standards, ultimately accelerating the launch of drugs for the treatment of neurodegenerative diseases.

In 2025, the North America Neurodegenerative Disease CDMO market was US$ million, while the Europe market stood at US$ million. North America accounted for % of the global market in 2025 and Europe for %. Europe’s share is expected to reach % by 2032, corresponding to a CAGR of % over the analysis period.

The global key players of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai, Fujirebio Holdings, GenSight Biologics, among others. In 2025, the top five players accounted for approximately % of global market revenue.

In terms of revenue, the top three players in North America accounted for about % of the market in 2025, while the top three in Europe held nearly %.

The global Neurodegenerative Disease CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

MARKET SEGMENTATION

By Company

AC Immune
Alterity Therapeutics
Biogen
Charles River Laboratories
Coave Therapeutics
Sysmex Corp
Donanemab
Eisai
Fujirebio Holdings
GenSight Biologics
Neuropore Therapies
Nevrargenics
PPD
Samsung Biologics
Sanofi(Vigil Neuroscience)

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Small Molecule Drug CDMO
Biopharmaceutical CDMO
Cell and Gene Therapy (CGT) CDMO
OtherS

Segment by Application

Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Neurodegenerative Disease CDMO value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032

1.2.2 Small Molecule Drug CDMO

1.2.3 Biopharmaceutical CDMO

1.2.4 Cell and Gene Therapy (CGT) CDMO

1.2.5 OtherS

1.3 Market by Application

1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032

1.3.2 Alzheimer's Disease

1.3.3 Parkinson's Disease

1.3.4 Huntington's Disease

1.3.5 Amyotrophic Lateral Sclerosis (ALS)

1.3.6 Multiple System Atrophy (MSA)

1.3.7 Progressive Supranuclear Palsy (PSP)

1.3.8 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurodegenerative Disease CDMO Market Perspective (2021-2032)

2.2 Global Market Size by Region: 2021 vs 2025 vs 2032

2.3 Global Neurodegenerative Disease CDMO Market Share by Revenue, by Region (2021-2026)

2.4 Global Neurodegenerative Disease CDMO Revenue Forecast by Region (2027-2032)

2.5 Major Regions and Emerging Markets Analysis

2.5.1 North America Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.2 Europe Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.3 China Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.4 Japan Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.5 Southeast Asia Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.6 India Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.7 South America Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

2.5.8 Middle East Neurodegenerative Disease CDMO Market Size and Prospective (2021-2032)

3 Breakdown Data by Type

3.1 Global Neurodegenerative Disease CDMO Historical Market Size by Type (2021-2026)

3.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2027-2032)

3.3 Representative Players for Different Types of Neurodegenerative Disease CDMO

4 Breakdown Data by Application

4.1 Global Neurodegenerative Disease CDMO Historical Market Size by Application (2021-2026)

4.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2027-2032)

4.3 New Sources of Growth in Neurodegenerative Disease CDMO Applications

5 Competitive Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Neurodegenerative Disease CDMO Players by Revenue (2021-2026)

5.1.2 Global Neurodegenerative Disease CDMO Market Share by Revenue, by Players (2021-2026)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Neurodegenerative Disease CDMO Revenue

5.4 Global Neurodegenerative Disease CDMO Market Concentration Analysis

5.4.1 Global Neurodegenerative Disease CDMO Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease CDMO Revenue in 2025

5.5 Global Key Players of Neurodegenerative Disease CDMO Head Offices and Areas Served

5.6 Global Key Players of Neurodegenerative Disease CDMO, Product and Application

5.7 Global Key Players of Neurodegenerative Disease CDMO, Date of Entry into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.1.2 North America Market Size by Type

6.1.2.1 North America Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.1.2.2 North America Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.1.3 North America Market Size by Application

6.1.3.1 North America Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.1.3.2 North America Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.1.4 North America Neurodegenerative Disease CDMO Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.2.2.2 Europe Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.2.3.2 Europe Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.2.4 Europe Neurodegenerative Disease CDMO Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.3.2 China Market Size by Type

6.3.2.1 China Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.3.2.2 China Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.3.3 China Market Size by Application

6.3.3.1 China Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.3.3.2 China Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.3.4 China Neurodegenerative Disease CDMO Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.4.2 Japan Market Size by Type

6.4.2.1 Japan Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.4.2.2 Japan Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.4.3 Japan Market Size by Application

6.4.3.1 Japan Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.4.3.2 Japan Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.4.4 Japan Neurodegenerative Disease CDMO Major Customers

6.4.5 Japan Market Trends and Opportunities

6.5 Southeast Asia Market: Players, Segments, Downstream and Major Customers

6.5.1 Southeast Asia Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.5.2 Southeast Asia Market Size by Type

6.5.2.1 Southeast Asia Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.5.2.2 Southeast Asia Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.5.3 Southeast Asia Market Size by Application

6.5.3.1 Southeast Asia Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.5.3.2 Southeast Asia Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.5.4 Southeast Asia Neurodegenerative Disease CDMO Major Customers

6.5.5 Southeast Asia Market Trends and Opportunities

6.6 India Market: Players, Segments, Downstream and Major Customers

6.6.1 India Neurodegenerative Disease CDMO Revenue by Company (2021-2026)

6.6.2 India Market Size by Type

6.6.2.1 India Neurodegenerative Disease CDMO Market Size by Type (2021-2026)

6.6.2.2 India Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

6.6.3 India Market Size by Application

6.6.3.1 India Neurodegenerative Disease CDMO Market Size by Application (2021-2026)

6.6.3.2 India Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

6.6.4 India Neurodegenerative Disease CDMO Major Customers

6.6.5 India Market Trends and Opportunities

7 Key Player Profiles

7.1 AC Immune

7.1.1 AC Immune Company Details

7.1.2 AC Immune Business Overview

7.1.3 AC Immune Neurodegenerative Disease CDMO Introduction

7.1.4 AC Immune Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.1.5 AC Immune Recent Development

7.2 Alterity Therapeutics

7.2.1 Alterity Therapeutics Company Details

7.2.2 Alterity Therapeutics Business Overview

7.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Introduction

7.2.4 Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.2.5 Alterity Therapeutics Recent Development

7.3 Biogen

7.3.1 Biogen Company Details

7.3.2 Biogen Business Overview

7.3.3 Biogen Neurodegenerative Disease CDMO Introduction

7.3.4 Biogen Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.3.5 Biogen Recent Development

7.4 Charles River Laboratories

7.4.1 Charles River Laboratories Company Details

7.4.2 Charles River Laboratories Business Overview

7.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Introduction

7.4.4 Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.4.5 Charles River Laboratories Recent Development

7.5 Coave Therapeutics

7.5.1 Coave Therapeutics Company Details

7.5.2 Coave Therapeutics Business Overview

7.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Introduction

7.5.4 Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.5.5 Coave Therapeutics Recent Development

7.6 Sysmex Corp

7.6.1 Sysmex Corp Company Details

7.6.2 Sysmex Corp Business Overview

7.6.3 Sysmex Corp Neurodegenerative Disease CDMO Introduction

7.6.4 Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.6.5 Sysmex Corp Recent Development

7.7 Donanemab

7.7.1 Donanemab Company Details

7.7.2 Donanemab Business Overview

7.7.3 Donanemab Neurodegenerative Disease CDMO Introduction

7.7.4 Donanemab Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.7.5 Donanemab Recent Development

7.8 Eisai

7.8.1 Eisai Company Details

7.8.2 Eisai Business Overview

7.8.3 Eisai Neurodegenerative Disease CDMO Introduction

7.8.4 Eisai Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.8.5 Eisai Recent Development

7.9 Fujirebio Holdings

7.9.1 Fujirebio Holdings Company Details

7.9.2 Fujirebio Holdings Business Overview

7.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Introduction

7.9.4 Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.9.5 Fujirebio Holdings Recent Development

7.10 GenSight Biologics

7.10.1 GenSight Biologics Company Details

7.10.2 GenSight Biologics Business Overview

7.10.3 GenSight Biologics Neurodegenerative Disease CDMO Introduction

7.10.4 GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.10.5 GenSight Biologics Recent Development

7.11 Neuropore Therapies

7.11.1 Neuropore Therapies Company Details

7.11.2 Neuropore Therapies Business Overview

7.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Introduction

7.11.4 Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.11.5 Neuropore Therapies Recent Development

7.12 Nevrargenics

7.12.1 Nevrargenics Company Details

7.12.2 Nevrargenics Business Overview

7.12.3 Nevrargenics Neurodegenerative Disease CDMO Introduction

7.12.4 Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.12.5 Nevrargenics Recent Development

7.13 PPD

7.13.1 PPD Company Details

7.13.2 PPD Business Overview

7.13.3 PPD Neurodegenerative Disease CDMO Introduction

7.13.4 PPD Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.13.5 PPD Recent Development

7.14 Samsung Biologics

7.14.1 Samsung Biologics Company Details

7.14.2 Samsung Biologics Business Overview

7.14.3 Samsung Biologics Neurodegenerative Disease CDMO Introduction

7.14.4 Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.14.5 Samsung Biologics Recent Development

7.15 Sanofi(Vigil Neuroscience)

7.15.1 Sanofi(Vigil Neuroscience) Company Details

7.15.2 Sanofi(Vigil Neuroscience) Business Overview

7.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Introduction

7.15.4 Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2021-2026)

7.15.5 Sanofi(Vigil Neuroscience) Recent Development

8 Neurodegenerative Disease CDMO Market Dynamics

8.1 Neurodegenerative Disease CDMO Industry Trends

8.2 Neurodegenerative Disease CDMO Market Drivers

8.3 Neurodegenerative Disease CDMO Market Challenges

8.4 Neurodegenerative Disease CDMO Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Global Neurodegenerative Disease CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 3. Global Market Neurodegenerative Disease CDMO Market Size (US$ Million) by Region:2021 vs 2025 vs 2032

Table 4. Global Neurodegenerative Disease CDMO Revenue (US$ Million) Market Share by Region (2021-2026)

Table 5. Global Neurodegenerative Disease CDMO Revenue Share by Region (2021-2026)

Table 6. Global Neurodegenerative Disease CDMO Revenue (US$ Million) Forecast by Region (2027-2032)

Table 7. Global Neurodegenerative Disease CDMO Revenue Share Forecast by Region (2027-2032)

Table 8. Global Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 9. Global Neurodegenerative Disease CDMO Market Share by Revenue, by Type (2021-2026)

Table 10. Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million)

Table 11. Global Neurodegenerative Disease CDMO Market Share by Revenue, by Type (2027-2032)

Table 12. Representative Players of Each Type

Table 13. Global Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 14. Global Neurodegenerative Disease CDMO Market Share by Revenue, by Application (2021-2026)

Table 15. Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million)

Table 16. Global Neurodegenerative Disease CDMO Market Share by Revenue, by Application (2027-2032)

Table 17. New Sources of Growth in Neurodegenerative Disease CDMO Applications

Table 18. Global Neurodegenerative Disease CDMO Revenue by Players (2021-2026) & (US$ Million)

Table 19. Global Neurodegenerative Disease CDMO Market Share by Players (2021-2026)

Table 20. Global Top Neurodegenerative Disease CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2025)

Table 21. Ranking of Global Top Neurodegenerative Disease CDMO Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Neurodegenerative Disease CDMO Revenue (CR5 and HHI) & (2021-2026)

Table 23. Global Key Players of Neurodegenerative Disease CDMO, Headquarters and Area Served

Table 24. Global Key Players of Neurodegenerative Disease CDMO, Product and Application

Table 25. Global Key Players of Neurodegenerative Disease CDMO, Date of Entry into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 28. North America Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 29. North America Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 30. North America Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 31. Europe Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 32. Europe Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 33. Europe Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 34. Europe Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 35. China Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 36. China Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 37. China Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 38. China Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 39. Japan Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 40. Japan Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 41. Japan Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 42. Japan Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 43. Southeast Asia Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 44. Southeast Asia Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 45. Southeast Asia Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 46. Southeast Asia Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 47. India Neurodegenerative Disease CDMO Revenue by Company (2021-2026) & (US$ Million)

Table 48. India Neurodegenerative Disease CDMO Market Share by Revenue, by Company (2021-2026)

Table 49. India Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million)

Table 50. India Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million)

Table 51. AC Immune Company Details

Table 52. AC Immune Business Overview

Table 53. AC Immune Neurodegenerative Disease CDMO Product

Table 54. AC Immune Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 55. AC Immune Recent Development

Table 56. Alterity Therapeutics Company Details

Table 57. Alterity Therapeutics Business Overview

Table 58. Alterity Therapeutics Neurodegenerative Disease CDMO Product

Table 59. Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 60. Alterity Therapeutics Recent Development

Table 61. Biogen Company Details

Table 62. Biogen Business Overview

Table 63. Biogen Neurodegenerative Disease CDMO Product

Table 64. Biogen Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 65. Biogen Recent Development

Table 66. Charles River Laboratories Company Details

Table 67. Charles River Laboratories Business Overview

Table 68. Charles River Laboratories Neurodegenerative Disease CDMO Product

Table 69. Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 70. Charles River Laboratories Recent Development

Table 71. Coave Therapeutics Company Details

Table 72. Coave Therapeutics Business Overview

Table 73. Coave Therapeutics Neurodegenerative Disease CDMO Product

Table 74. Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 75. Coave Therapeutics Recent Development

Table 76. Sysmex Corp Company Details

Table 77. Sysmex Corp Business Overview

Table 78. Sysmex Corp Neurodegenerative Disease CDMO Product

Table 79. Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 80. Sysmex Corp Recent Development

Table 81. Donanemab Company Details

Table 82. Donanemab Business Overview

Table 83. Donanemab Neurodegenerative Disease CDMO Product

Table 84. Donanemab Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 85. Donanemab Recent Development

Table 86. Eisai Company Details

Table 87. Eisai Business Overview

Table 88. Eisai Neurodegenerative Disease CDMO Product

Table 89. Eisai Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 90. Eisai Recent Development

Table 91. Fujirebio Holdings Company Details

Table 92. Fujirebio Holdings Business Overview

Table 93. Fujirebio Holdings Neurodegenerative Disease CDMO Product

Table 94. Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 95. Fujirebio Holdings Recent Development

Table 96. GenSight Biologics Company Details

Table 97. GenSight Biologics Business Overview

Table 98. GenSight Biologics Neurodegenerative Disease CDMO Product

Table 99. GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 100. GenSight Biologics Recent Development

Table 101. Neuropore Therapies Company Details

Table 102. Neuropore Therapies Business Overview

Table 103. Neuropore Therapies Neurodegenerative Disease CDMO Product

Table 104. Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 105. Neuropore Therapies Recent Development

Table 106. Nevrargenics Company Details

Table 107. Nevrargenics Business Overview

Table 108. Nevrargenics Neurodegenerative Disease CDMO Product

Table 109. Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 110. Nevrargenics Recent Development

Table 111. PPD Company Details

Table 112. PPD Business Overview

Table 113. PPD Neurodegenerative Disease CDMO Product

Table 114. PPD Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 115. PPD Recent Development

Table 116. Samsung Biologics Company Details

Table 117. Samsung Biologics Business Overview

Table 118. Samsung Biologics Neurodegenerative Disease CDMO Product

Table 119. Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 120. Samsung Biologics Recent Development

Table 121. Sanofi(Vigil Neuroscience) Company Details

Table 122. Sanofi(Vigil Neuroscience) Business Overview

Table 123. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product

Table 124. Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2021-2026) & (US$ Million)

Table 125. Sanofi(Vigil Neuroscience) Recent Development

Table 126. Neurodegenerative Disease CDMO Market Trends

Table 127. Neurodegenerative Disease CDMO Market Drivers

Table 128. Neurodegenerative Disease CDMO Market Challenges

Table 129. Neurodegenerative Disease CDMO Market Restraints

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

List of Figures

Figure 1. Neurodegenerative Disease CDMO Product Picture

Figure 2. Global Neurodegenerative Disease CDMO Market Share by Type: 2025 vs 2032

Figure 3. Small Molecule Drug CDMO Features

Figure 4. Biopharmaceutical CDMO Features

Figure 5. Cell and Gene Therapy (CGT) CDMO Features

Figure 6. OtherS Features

Figure 7. Global Neurodegenerative Disease CDMO Market Share by Application: 2025 vs 2032

Figure 8. Alzheimer's Disease

Figure 9. Parkinson's Disease

Figure 10. Huntington's Disease

Figure 11. Amyotrophic Lateral Sclerosis (ALS)

Figure 12. Multiple System Atrophy (MSA)

Figure 13. Progressive Supranuclear Palsy (PSP)

Figure 14. Others

Figure 15. Neurodegenerative Disease CDMO Report Years Considered

Figure 16. Global Neurodegenerative Disease CDMO Market Size (US$ Million), Year-over-Year: 2021-2032

Figure 17. Global Neurodegenerative Disease CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 18. Global Neurodegenerative Disease CDMO Market Share by Revenue, by Region: 2021 vs 2025

Figure 19. North America Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 20. Europe Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 21. China Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 22. Japan Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 23. Southeast Asia Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 24. India Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 25. South America Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 26. Middle East Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2021-2032)

Figure 27. Global Neurodegenerative Disease CDMO Market Share by Players in 2025

Figure 28. Global Top Neurodegenerative Disease CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2025)

Figure 29. The Top 10 and 5 Players Market Share by Neurodegenerative Disease CDMO Revenue in 2025

Figure 30. North America Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 31. North America Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 32. Europe Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 33. Europe Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 34. China Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 35. China Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 36. Japan Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 37. Japan Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 38. Southeast Asia Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 39. Southeast Asia Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 40. India Neurodegenerative Disease CDMO Market Share by Type (2021-2026)

Figure 41. India Neurodegenerative Disease CDMO Market Share by Application (2021-2026)

Figure 42. AC Immune Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 43. Alterity Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 44. Biogen Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 45. Charles River Laboratories Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 46. Coave Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 47. Sysmex Corp Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 48. Donanemab Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 49. Eisai Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 50. Fujirebio Holdings Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 51. GenSight Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 52. Neuropore Therapies Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 53. Nevrargenics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 54. PPD Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 55. Samsung Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 56. Sanofi(Vigil Neuroscience) Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2021-2026)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Neurodegenerative Disease CDMO in 2032? zhanKai

The global market size of Neurodegenerative Disease CDMO in 2032 was 1220 Million USD.

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Neurodegenerative Disease CDMO market size from 2026 to 2032? shouQi

What was the global market size of Neurodegenerative Disease CDMO in 2026? shouQi

Which companies rank high in the global Neurodegenerative Disease CDMO market? shouQi

Related Reports

Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 133
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 112
USD 2900.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 110
USD 3950.00
(Single User License)
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neurodegenerative Disease CDMO market size was US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published Date: 2025-07-11
Pages: 99
USD 4250.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published Date: 2025-07-11
Pages: 118
USD 3950.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-11
Pages: 140
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2025
The global market for Neurodegenerative Disease CDMO was valued at US$ 735 million in the year 2024 and is projected to reach a revised size of US$ 1149 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published Date: 2025-07-11
Pages: 86
USD 2900.00
(Single User License)

Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 133
USD 4900.00 (Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-12
Pages: 112
USD 2900.00 (Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-09
Pages: 110
USD 3950.00 (Single User License)
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neurodegenerative Disease CDMO market size was US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published: 2025-07-11
Pages: 99
USD 4250.00 (Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published: 2025-07-11
Pages: 118
USD 3950.00 (Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-11
Pages: 140
USD 4900.00 (Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2025
The global market for Neurodegenerative Disease CDMO was valued at US$ 735 million in the year 2024 and is projected to reach a revised size of US$ 1149 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published: 2025-07-11
Pages: 86
USD 2900.00 (Single User License)